These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 11589476)

  • 1. Host immune reactivity and antifungal chemotherapy: the power of being together.
    Romani L
    J Chemother; 2001 Aug; 13(4):347-53. PubMed ID: 11589476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines and fungal infections.
    Antachopoulos C; Roilides E
    Br J Haematol; 2005 Jun; 129(5):583-96. PubMed ID: 15916680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal immunotherapy and immunomodulation: a double-hitter approach to deal with invasive fungal infections.
    Hamad M
    Scand J Immunol; 2008 Jun; 67(6):533-43. PubMed ID: 18397201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of Fungal Infections.
    Datta K; Hamad M
    Immunol Invest; 2015; 44(8):738-76. PubMed ID: 26575463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunocompromised hosts: immunopharmacology of modern antifungals.
    Ben-Ami R; Lewis RE; Kontoyiannis DP
    Clin Infect Dis; 2008 Jul; 47(2):226-35. PubMed ID: 18540822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of fungal infections in the immunocompromised host.
    Mahfouz T; Anaissie E
    Curr Opin Investig Drugs; 2003 Aug; 4(8):974-90. PubMed ID: 14508882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination immunotherapy and antifungal chemotherapy.
    Stevens DA
    Clin Infect Dis; 1998 Jun; 26(6):1266-9. PubMed ID: 9636844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of antifungal resistance and its impact on clinical practice.
    Alcazar-Fuoli L; Mellado E
    Br J Haematol; 2014 Aug; 166(4):471-84. PubMed ID: 24749533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in antifungal prevention and treatment.
    Groll AH; Tragiannidis A
    Semin Hematol; 2009 Jul; 46(3):212-29. PubMed ID: 19549575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of efficacy trials of cytokines in combination with antifungal drugs.
    Kullberg BJ; Oude Lashof AM; Netea MG
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S218-23. PubMed ID: 15546121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 1 and type 2 cytokines: from basic science to fungal infections.
    Murphy JW; Bistoni F; Deepe GS; Blackstock RA; Buchanan K; Ashman RB; Romani L; Mencacci A; Cenci E; Fè d'Ostiani C; Del Sero G; Calich VL; Kashino SS
    Med Mycol; 1998; 36 Suppl 1():109-18. PubMed ID: 9988499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices.
    Singh N
    Clin Infect Dis; 2001 Nov; 33(10):1692-6. PubMed ID: 11641825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of infections caused by rare filamentous fungi.
    Katragkou A; Roilides E
    Clin Microbiol Infect; 2012 Feb; 18(2):134-9. PubMed ID: 22044625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
    Metcalf SC; Dockrell DH
    J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis.
    Mencacci A; Cenci E; Bacci A; Bistoni F; Romani L
    J Infect Dis; 2000 Feb; 181(2):686-94. PubMed ID: 10669356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of immunoreconstitution in the management of refractory opportunistic fungal infections.
    Roilides E; Dignani MC; Anaissie EJ; Rex JH
    Med Mycol; 1998; 36 Suppl 1():12-25. PubMed ID: 9988488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of immunocompromised patients with evidence of an invasive mycosis.
    Walsh TJ
    Hematol Oncol Clin North Am; 1993 Oct; 7(5):1003-26. PubMed ID: 8226563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current drug therapy of systemic mycoses: a review.
    Yonga G
    East Afr Med J; 1995 Jun; 72(6):394-8. PubMed ID: 7498014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances and challenges in management of invasive mycoses.
    Patterson TF
    Lancet; 2005 Sep 17-23; 366(9490):1013-25. PubMed ID: 16168784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immune response to fungal infections.
    Shoham S; Levitz SM
    Br J Haematol; 2005 Jun; 129(5):569-82. PubMed ID: 15916679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.